Consequences of the COVID-19 pandemic on lung cancer care and patient health in a German lung cancer center: results from a cross-sectional questionnaire.
Aged
Ambulatory Care
/ trends
Appointments and Schedules
COVID-19
/ diagnosis
COVID-19 Vaccines
/ therapeutic use
Cross-Sectional Studies
Delivery of Health Care, Integrated
/ trends
Female
Germany
Health Care Surveys
Health Services Accessibility
/ trends
Health Status
Humans
Lung Neoplasms
/ diagnosis
Male
Masks
/ trends
Medical Oncology
/ trends
Middle Aged
Physical Therapy Modalities
/ trends
Practice Patterns, Physicians'
/ trends
Respiratory Therapy
/ trends
Social Behavior
Time Factors
Time-to-Treatment
/ trends
Corona virus
Quarantine
SARS-CoV-2
Social distancing
Thoracic malignancies
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
29 Jan 2022
29 Jan 2022
Historique:
received:
17
02
2021
accepted:
10
01
2022
entrez:
30
1
2022
pubmed:
31
1
2022
medline:
4
2
2022
Statut:
epublish
Résumé
The novel coronavirus SARS-CoV-2 has caused a global COVID-19 pandemic, leading to worldwide changes in public health measures. In addition to changes in the public sector (lockdowns, contact restrictions), hospitals modified care to minimize risk of infection and to mobilize resources for COVID-19 patients. Our study aimed to assess the impact of these measures on access to care and behaviour of patients with thoracic malignancies. Thoracic oncology patients were surveyed in October 2020 using paper-based questionnaires to assess access to ambulatory care services and tumor-directed therapy during the COVID-19 pandemic. Additionally, behaviour regarding social distancing and wearing of face masks were assessed, as well as COVID-19 exposure, testing and vaccination. Results are presented as absolute and relative frequencies for categorical variables and means with standard deviation for numerical variables. We used t-test, and ANOVA to compare differences in metric variables and Chi 93 of 245 (38%) patients surveyed completed the questionnaire. Respiration therapy and physical therapy were unavailable for 57% to 70% of patients during March/April. Appointments for tumor-directed therapy, tumor imaging, and follow-up care were postponed or cancelled for 18.9%, 13.6%, and 14.8% of patients, respectively. Patients reported their general health as mostly unaffected. The majority of patients surveyed did not report reducing their contacts with family. The majority reduced contact with friends. Most patients wore community masks, although a significant proportion reported respiratory difficulties during prolonged mask-wearing. 74 patients (80%) reported willingness to be vaccinated against SARS-CoV-2. This survey provides insights into the patient experience during the second wave of the COVID-19 pandemic in Munich, Germany. Most patients reported no negative changes to cancer treatments or general health; however, allied health services were greatly impacted. Patients reported gaps in social distancing, but were prepared to wear community masks. The willingness to get vaccinated against SARS-CoV-2 was high. This information is not only of high relevance to policy makers, but also to health care providers.
Sections du résumé
BACKGROUND
BACKGROUND
The novel coronavirus SARS-CoV-2 has caused a global COVID-19 pandemic, leading to worldwide changes in public health measures. In addition to changes in the public sector (lockdowns, contact restrictions), hospitals modified care to minimize risk of infection and to mobilize resources for COVID-19 patients. Our study aimed to assess the impact of these measures on access to care and behaviour of patients with thoracic malignancies.
METHODS
METHODS
Thoracic oncology patients were surveyed in October 2020 using paper-based questionnaires to assess access to ambulatory care services and tumor-directed therapy during the COVID-19 pandemic. Additionally, behaviour regarding social distancing and wearing of face masks were assessed, as well as COVID-19 exposure, testing and vaccination. Results are presented as absolute and relative frequencies for categorical variables and means with standard deviation for numerical variables. We used t-test, and ANOVA to compare differences in metric variables and Chi
RESULTS
RESULTS
93 of 245 (38%) patients surveyed completed the questionnaire. Respiration therapy and physical therapy were unavailable for 57% to 70% of patients during March/April. Appointments for tumor-directed therapy, tumor imaging, and follow-up care were postponed or cancelled for 18.9%, 13.6%, and 14.8% of patients, respectively. Patients reported their general health as mostly unaffected. The majority of patients surveyed did not report reducing their contacts with family. The majority reduced contact with friends. Most patients wore community masks, although a significant proportion reported respiratory difficulties during prolonged mask-wearing. 74 patients (80%) reported willingness to be vaccinated against SARS-CoV-2.
CONCLUSIONS
CONCLUSIONS
This survey provides insights into the patient experience during the second wave of the COVID-19 pandemic in Munich, Germany. Most patients reported no negative changes to cancer treatments or general health; however, allied health services were greatly impacted. Patients reported gaps in social distancing, but were prepared to wear community masks. The willingness to get vaccinated against SARS-CoV-2 was high. This information is not only of high relevance to policy makers, but also to health care providers.
Identifiants
pubmed: 35093079
doi: 10.1186/s12931-022-01931-z
pii: 10.1186/s12931-022-01931-z
pmc: PMC8799980
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
18Informations de copyright
© 2022. The Author(s).
Références
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
Respiration. 2021;100(1):90-92
pubmed: 33370724
Prev Med. 2017 Nov;104:124-132
pubmed: 28716654
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
JCO Clin Cancer Inform. 2020 Nov;4:1059-1071
pubmed: 33253013
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
JCO Glob Oncol. 2020 Sep;6:1428-1438
pubmed: 32986516
Eur J Cancer. 2020 Sep;136:132-139
pubmed: 32683273
Am J Epidemiol. 2011 Mar 15;173(6):676-82
pubmed: 21330339
Nat Rev Clin Oncol. 2021 Jan;18(1):3-4
pubmed: 33097915
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
JCO Oncol Pract. 2020 Oct;16(10):656-664
pubmed: 32603253
Eur J Health Econ. 2020 Sep;21(7):977-982
pubmed: 32591957